Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVEAL-1: AGN-199201 for persistent erythema in rosacea
NCT02131636Phase 3Completed
- Sponsor
- Allergan
- Start
- May 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of oxymetazoline in Erythematotelangiectatic Rosacea (ETR), sponsored by Allergan. Started May 2014; status: completed.
02
Drugs
oxymetazoline
03
Conditions
Erythematotelangiectatic Rosacea (ETR)
Beyond the preview
Go deeper on NCT02131636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02131636.